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Abstract
Introduction The androgen receptor (AR) gene exon 1 CAG
repeat polymorphism encodes a string of 9–32 glutamines.
Women with germline BRCA1 mutations who carry at least one
AR allele with 28 or more repeats have been reported to have
an earlier age at onset of breast cancer.
Methods A total of 604 living female Australian and British
BRCA1  and/or  BRCA2  mutation carriers from 376 families
were genotyped for the AR  CAG repeat polymorphism. The
association between AR  genotype and disease risk was
assessed using Cox regression. AR genotype was analyzed as
a dichotomous covariate using cut-points previously reported to
be associated with increased risk among BRCA1  mutation
carriers, and as a continuous variable considering smaller allele,
larger allele and average allele size.
Results There was no evidence that the AR  CAG repeat
polymorphism modified disease risk in the 376 BRCA1 or 219
BRCA2 mutation carriers screened successfully. The rate ratio
associated with possession of at least one allele with 28 or more
CAG repeats was 0.74 (95% confidence interval 0.42–1.29; P
= 0.3) for BRCA1 carriers, and 1.12 (95% confidence interval
0.55–2.25; P = 0.8) for BRCA2 carriers.
Conclusion The AR exon 1 CAG repeat polymorphism does not
appear to have an effect on breast cancer risk in BRCA1 or
BRCA2 mutation carriers.
Keywords: AR, BRCA1, BRCA2, modifier
Introduction
A CAG length polymorphism within exon 1 of the androgen
receptor (AR) gene encodes a string of 9–32 glutamines.
Even within this normal range, CAG repeat number is
inversely associated with AR-mediated transcriptional acti-
vation in vitro [1,2]. Involvement of the AR in breast tumour-
igenesis is suggested by the existence of inactivating
germline mutations in the hormone-binding domain in male
breast cancer patients [3,4], and by splice variants that dis-
rupt the transactivation domain in female breast tumours
and tumour cell lines [5].
There is evidence that suggests an association between
longer  AR  CAG repeat length – representative of less
active AR – and breast cancer risk at the population level
(for review, see Lillie and coworkers [6]). Using slightly var-
iable definitions of shorter and longer allele size across
studies, one study reported a significant twofold increased
AR = androgen receptor; CI = confidence interval; RR = rate ratio.Breast Cancer Research    Vol 7 No 2    Spurdle et al.
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risk for breast cancer, another three studies reported a
slightly increased risk for breast cancer (1.2- to 1.4-fold),
and another reported a 1.7-fold increased risk limited to
individuals with a first-degree family history of breast can-
cer [6].
Several studies have been undertaken to assess the role of
the CAG repeat polymorphism as a modifier of breast can-
cer risk in BRCA1  and  BRCA2  mutation carriers. The
hypothesis-generating study [7] examined AR CAG length
in 304 female BRCA1 mutation carriers (54% with breast
cancer), and assessed breast cancer risk associated with
CAG length as a continuous variable, and at a number of
different cut-points. That study reported a 1.8-fold relative
risk (95% confidence interval [CI] 1.1–3.1; P  = 0.03)
among the small subgroup of women with at least one AR
allele of 28 or more CAG repeats in length, with relative
risks of 2.6 (95% CI 1.5–4.7; P < 0.001) and 4.5 (95% CI
1.3–15.2; P = 0.02) for the cut-points ≥ 29 CAG repeats
and ≥ 30 CAG repeats, respectively. Subsequent studies
have reported conflicting results. A relative risk of 1.1 (95%
CI 0.5–2.6) was observed for women with 28 or more CAG
repeats from a pooled analysis of 188 BRCA1 and BRCA2
mutation carriers [8], whereas a study of 227 BRCA1 and
BRCA2  mutation carriers reported shorter mean CAG
repeat number in women with breast cancer diagnosed
before age 42 years as compared with those diagnosed
after this age [9].
It has been hypothesized that AR alleles with decreased
transactivation might act directly to result in decreased
breast cell proliferation, or possibly indirectly via an endo-
crine or paracrine mechanism whereby altered levels of cir-
culating or stromal hormones might affect mammary
epithelial growth [7]. Subsequent biochemical studies
reported a protein–protein interaction between the AR pro-
tein and particular regions of both the BRCA2 and BRCA1
proteins. BRCA2 has been reported to enhance androgen-
dependent AR activity [10]. Although that study also
reported that an expressed truncated BRCA2 protein
encoded by the BRCA2  L1042X mutation failed to
enhance AR transactivation [10], it did not examine the
effect of BRCA2  mutation position in general, or which
domains of BRCA2 are required for the BRCA2–AR
interaction.
BRCA1 has also been reported to enhance androgen-
dependent AR transactivation [11,12]. Mammalian two-
hybrid assays have shown that BRCA1 amino acids 231–
1314 and 1560–1863 are responsible for this direct inter-
action, with BRCA1 region 758–1064 observed to bind
specifically to the AR amino-terminal domain containing the
glutamine repeat [11]. Androgen response assays indi-
cated that, although BRCA1 mutations across the gene all
reduce AR activity enhancement as compared with the
wild-type, the effect was more marked for mutations up to
amino acid 1365 [11]. This was particularly true for a muta-
tion that caused truncation at amino acid 772 within the
BRCA1–AR amino-terminus interaction domain, which had
20% activity relative to the wild-type BRCA1. The effect of
the AR CAG repeat length on BRCA1–AR interactions has
not yet been investigated. However, molecular studies pro-
vide some support for a biochemical interaction between
AR CAG repeat length and BRCA1 mutation status, in that
the decreased AR transactivation observed in vitro with
increasing glutamine length was only observed in the
absence of coexpressed BRCA1 [12].
These data suggest that an association of AR CAG repeat
length with increased breast cancer risk may be found only
in BRCA1 or BRCA2 mutation carriers (and not individual
germline without BRCA1 or BRCA2 mutations), and that
AR-dependent modification of cancer risk in BRCA1 and
BRCA2 mutation carriers may differ according to which
gene is mutated, and the mutation position relative to AR-
binding site. To evaluate further the evidence for an associ-
ation between AR CAG repeat length and breast cancer
risk in BRCA1 and BRCA2 mutation carriers, we geno-
typed the polymorphism in a large series of female mutation
carriers.
Methods
Subjects
The distribution of samples according to source, gene and
cancer status is shown in Table 1.
A total of 604 living female Australian and British carriers of
pathogenic BRCA1 or BRCA2 mutations were identified in
376 families from the following sources: the Epidemiologi-
cal study of BRCA1  and  BRCA2  Mutation Carriers
(EMBRACE; http://www.srl.cam.ac.uk/genepi/embracein
dex.htm), the Kathleen Cuningham Consortium for
Research into Familial Breast Cancer (kConFaB; http://
www.kconfab.org), the Australian Jewish Breast Cancer
Study (AJBCS) [13], and the Australian Breast Cancer
Family Study (ABCFS) [14,15]. EMBRACE recruits partic-
ipants from among women and men referred for genetic
testing at clinical genetics centres in the UK and Eire.
kConFaB recruits participants from multiple-case breast
and ovarian cancer families referred for genetic testing at
family cancer clinics in Australia and New Zealand. AJBCS
recruits Ashkenazi Jewish women reporting a personal or
family history of breast or ovarian cancer in a first- or sec-
ond-degree relative, and living in Melbourne or Sydney,
Australia. Finally, ABCFS is a population-based case–con-
trol-family study that includes women with a first primary
breast cancer recruited through the Victorian and New
South Wales cancer registries, and their affected and unaf-
fected relatives. Apart from index cases recruited throughAvailable online http://breast-cancer-research.com/content/7/2/R176
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cancer registries for the ABCFS, the cancer status of par-
ticipants was based on self-report.
For samples recruited through EMBRACE, a pathogenic
mutation was defined as an established disease-causing
mutation under the classification scheme used by Breast
Cancer Information Core http://research.nhgri.nih.gov/bic/
. For samples recruited through kConFaB, AJBCS and
ABCFS, mutations were classified as pathogenic accord-
ing to the criteria established by kConfab http://www.kcon
fab.org/progress/classification.asp. Specifically, the crite-
ria specify the following as being pathogenic: all truncating
mutations, unless there is clear evidence that the mutation
is a single nucleotide polymorphism (e.g. terminal BRCA2
variant); and any variant that is well characterized in family
studies of multiple generations, and not found in control
individuals, that results in a nonconservative amino acid
substitution, and occurs in a residue conserved across
species and in a functional domain. All mutations included
in the study that were shared across sites were classified
as pathogenic according to both routes of definition.
Within Australia, ethical approvals were obtained from the
ethics committees of the Peter MacCallum Cancer Insti-
tute, The Prince of Wales Hospital, The University of Mel-
bourne, The Cancer Council New South Wales, The
Cancer Council Victoria and the Queensland Institute of
Medical Research. Ethical approval for the EMBRACE
study was obtained from the Eastern Multicentre Research
Ethics Committee and the relevant local ethics committees.
Written informed consent was obtained from each
participant.
Molecular methods
The AR exon 1 CAG repeat length was measured by fluo-
rescent polymerase chain reaction PAGE methodology,
using the ABI Prism 373 Genescan (Applied Biosystems,
Foster City, CA, USA) and Genotyper systems (Applied
Biosystems). Details of this method were previously
reported [16]. Genotyping was successful for 375 out of
382 (98%) BRCA1  carriers, 218 out of 221 (99%)
BRCA2 carriers, and the single carrier of both a BRCA1
and a BRCA2 mutation.
Statistical methods
Individuals with a first diagnosis of primary invasive breast
cancer were considered to be affected, whereas individu-
als with no reported breast or ovarian cancer were cen-
sored at age at interview. Individuals with a first diagnosis
of primary ovarian cancer were censored as unaffected at
age at onset of ovarian cancer, and selected analyses were
also performed in which individuals with a first primary diag-
nosis of ovarian cancer were excluded. All individuals were
censored at age of prophylactic mastectomy. Individuals
reporting prophylactic surgery included a single BRCA2
carrier who was subsequently diagnosed with multiple
breast cancers 4 and 5 years after surgery, and an addi-
tional 12 unaffected individuals (7 BRCA1 and 5 BRCA2
carriers) with surgery 1–11 years before interview (average
3 years). Prophylactic oophorectomy of affected and
Table 1
Characteristics of study subjects
Sample sources BRCA1 BRCA2 BRCA1 and BRCA2a
n (% of total) n (% of total) n
EMBRACE 247 (64) 92 (42) 0
kConFaB 96 (25) 84 (38) 0
AJBCS 19 (5) 22 (10) 0
ABCFS 20 (5) 23 (10) 1
Total 382 221 1
Affected breast cancerb 205 (54) 125 (57) 1
Affected ovarian cancerb 24 (6) 8 (4) 0
Number of families 257 118 1
Questionnaire information on potential confounders was available for 344 BRCA1 carriers (239 EMBRACE, 80 kConFaB, 10 AJBCS and 15 
ABCFS) and 200 BRCA2 carriers (92 EMBRACE, 76 kConFaB, 12 AJBCS, and 20 ABCFS). aOne individual was found to carry a deleterious 
mutation in both BRCA1 and BRCA2 [19]. bCancer type refers to first primary cancer diagnosis. One BRCA2 carrier with breast cancer was 
censored as unaffected at age of prior mastectomy. ABCFS, Australian Breast Cancer Family Study; AJBCS, Australian Jewish Breast Cancer 
study; EMBRACE, Evaluation of Mutant BRCA Carrier Epidemiology study; kConFaB, Kathleen Cuningham Consortium for Research into Familial 
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unaffected individuals was controlled for by adjustment as
a time-dependent covariate, as described below.
Linear regression was used to assess the association of
AR CAG repeat length (smaller allele size, larger allele size
and average allele size) with potential confounders within
the subset of 364 BRCA1 carriers and 209 BRCA2 carri-
ers for whom information was available. The potential con-
founders included year of birth (categorized into subgroups
1910–1949, 1950–1959 and 1960–1979), age at
menarche (categorized as ≤ 11, 11.5–12, 12.5–13, 13.5–
14 or ≥ 14.5 years), oral contraceptive pill use (ever/never)
and parity (categorized as 0 or ≥ 1 live births before cen-
sored age). Questionnaire information was available from
participants on age at first and last live birth, but not age at
each live birth. Hence, it was not possible to assess asso-
ciation with parity as an absolute number of live births
before censored age, but rather only as a never/ever varia-
ble. Associations were assessed separately for affected
and unaffected women.
The primary analyses of association between AR genotype
and disease risk were performed using Cox regression with
time to breast cancer onset as the end-point. AR CAG
repeat length was defined as follows: a binary variable,
defined by cut-points investigated in the hypothesis-gener-
ating study conducted by Rebbeck and coworkers [7]
(namely one or more allele of ≥ 28 CAG repeats, ≥ 29 CAG
repeats, or ≥ 30 CAG repeats); or a continuous variable,
using the length of the smaller of the two alleles (AR small
CAG), the larger of the two alleles (AR large CAG), and the
average length of a participant's two alleles (AR average
CAG). Rate ratios (RRs) and 95% CIs were estimated with
adjustment for source group (as indicated in Table 1) and
ethnicity (non-Jewish Caucasian, Jewish, other). Analyses
were complicated by the fact that more than one mutation
carrier could come from the same family and could not
therefore be considered independent. Standard Cox
regression provides unbiased RR estimates but their stand-
ard errors and CIs are incorrect. This was rectified by com-
puting the confidence limits for the RRs using Huber's
sandwich estimator of the covariance matrix [17]. This
allows for variation between carriers from the same family
without modelling their dependence explicitly. Further anal-
yses adjusted for oophorectomy and parity as time-
dependent covariates, and for age at menarche, oral con-
traceptive pill use and year of birth. Oophorectomy before
censored age at interview or diagnosis of breast cancer
was reported by 39 BRCA1  carriers (10 with primary
breast cancer) and 21 BRCA2  carriers (9 with primary
breast cancer) with genotype information available.
RRs were estimated separately for BRCA1 and BRCA2
carriers, including in both analyses the single individual with
a mutation in both genes. Models adjusting for only group
and ethnicity included all individuals with genotype informa-
tion, namely 376 BRCA1 carriers (with 200 events) and
219 BRCA2 carriers (with 122 events). The sample size for
BRCA1  carriers with a putative risk allele was 28 (14
events) for the ≥ 28 CAG cut-point, 26 (13 events) for the
≥ 29 CAG cut-point, and 11 (4 events) for the ≥ 30 CAG
cut-point. Similarly, for BRCA2  carriers it was 17 (10
events) for the ≥ 28 CAG cut-point, 14 (7 events) for the ≥
29 CAG cutpoint, and 11 (5 events) for the ≥ 30 CAG cut-
point. Full models adjusting for year of birth and additional
hormonal variables included the 364 BRCA1  and 219
BRCA2 carriers with full information on potential confound-
ers, comprising 193 and 116 events, respectively.
In addition, analyses were carried out separately for sub-
groups of BRCA1 and BRCA2 carriers defined by muta-
tion position in relation to proposed AR-binding domains,
and/or in vitro data regarding mutation effect on AR trans-
activation [10,11]. For BRCA1, subgroups were defined by
the mutation position either relative to amino acid 1365 (<
or ≥ nucleotide 4213), because mutations 5' of amino acid
1365 have been shown to have a markedly decreased
effect on AR transactivation [11]. This created subgroups
including 314 and 62 individuals. In addition, BRCA1 sub-
groups were defined by mutation relative to amino acid
1065 (< or ≥ nucleotide 3311), because this defines the 3'
end of the BRCA1 fragment shown in vitro to bind the AR
amino-terminal domain containing the CAG-encoded poly-
glutamine tract [11], creating subgroups of 210 and 166
individuals. BRCA2 subgroups were defined by mutation
relative to amino acid 1042 (< or ≥ nucleotide 3352),
because it has been shown that the BRCA2 L1042X muta-
tion does not enhance AR transactivation [10]. Subgroup
sample sizes were 42 and 177. For both BRCA1  and
BRCA2 subgroup analyses, the 3' and 5' subgroups were
termed domain 1 and domain 2, respectively. Protein trun-
cating and splice mutations were stratified into domain 1 or
domain 2 according to their nucleotide/amino acid posi-
tion, whereas all missense mutations were included in
domain 2 because these nontruncating mutations may act
in a dominant-negative manner.
Although the primary analysis provides a valid test of the
association between a genotype and disease risk, it may
not provide a consistent estimate of the RR because the
disease status of the individuals may have affected the like-
lihood of ascertainment (for the non-population-based
studies). Oversampling of affected individuals is likely, as is
presentation of affected carriers at later mean age than
unaffected carriers. To correct for this potential bias, we
also conducted secondary analyses using the weighted
Cox regression approach as described by Antoniou and
coworkers (unpublished data), in which individuals are
weighted such that the observed breast cancer incidence
rates in the study sample are consistent with establishedAvailable online http://breast-cancer-research.com/content/7/2/R176
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breast cancer risk estimates for BRCA1 and BRCA2 muta-
tion carriers. Antoniou and coworkers (unpublished data)
have shown that this approach gives estimates that are
close to unbiased, but with some loss of power as com-
pared with the standard unweighted approach. Weights
were computed separately for BRCA1 and BRCA2 muta-
tion carriers using the breast cancer incidence rate esti-
mates reported in the meta-analysis conducted by
Antoniou et al. [18]. A global set of weights was computed
because the number of mutation carriers by study was too
small to compute reliable study-specific weights. Moreover,
Antoniou et al. [18] found no significant differences in the
BRCA1 and BRCA2 cancer risks by country or study cen-
tre. As for unweighted analyses, confidence limits for the
risk ratio were calculated using a robust variance approach
to allow for the dependence among individuals.
We evaluated the power of detecting the effects reported
by Rebbeck and coworkers [7] in our samples of BRCA1
and BRCA2 mutation carriers using simulations. For this
purpose, we assumed the age distribution of the affected
and unaffected carriers in our sample (Table 1) and simu-
lated among them risk factors with risk ratios 1.8 and 2.6
and the frequencies for the ≥ 28 and ≥ 29 CAG cut-points
observed in our sample. The data were then analyzed using
unweighted Cox regression. We conducted 1000 simula-
tions per model. More details about the simulations are
available from the authors of the present report. The power
of detecting risk ratios of 1.8 and 2.6 was estimated to be
51% and 92%, respectively, for the sample of BRCA1
mutation carriers and 28% and 78% for the sample of
BRCA2 mutation carriers.
R version 1.9.0 (R Foundation for Statistical Computing,
Vienna, Austria) was used to perform the unweighted Cox
regression, and STATA version 7 (Stata Corporation, Col-
lege Station, TX, USA) was used for the weighted analyses.
Results
The AR CAG length ranged from 8 to 36 repeats. There
was little power to assess potential confounding or risk
associated with the cut-point ≥ 30 CAG repeats, because
only 11 BRCA1 and 11 BRCA2 carriers had at least one
allele of this size. There was no evidence for an association
between AR CAG repeat length and year of birth, age at
menarche, or parity. There was marginal evidence for a pre-
ponderance of smaller alleles among affected BRCA2 car-
riers who reported using the oral contraceptive pill (P =
0.03), but this association was not seen in unaffected indi-
viduals or in BRCA1 affected or unaffected carriers (P >
0.2).
The estimated rate ratios associated with AR CAG repeat
length are given in Tables 2 and 3. Risk estimates using the
weighted Cox regression approach were very similar to the
unweighted estimates, and for simplicity the unweighted
estimates are shown. No associations were observed for
alleles ≥ 28 CAG repeats or ≥ 29 CAG repeats – cut-
points previously reported to be associated with risk. Esti-
mated RRs were close to and not significantly different
from 1 (all P > 0.3) and were in most instances less than 1.
The number of individuals with ≥ 30 CAG repeats was too
small to provide reliable risk estimates, but point estimates
(0.49 [P = 0.1] for BRCA1, 0.69 [P = 0.5] for BRCA2)
provided no evidence for increased risk associated with
these large alleles. When AR CAG repeat length was con-
sidered as a continuous variable, there was no association
either with average repeat length or with the length of the
shorter or longer allele (P ≥ 0.2). There was little difference
between the estimates adjusted only for source group and
ethnicity, and those adjusted also for year of birth, and hor-
monal variables oophorectomy, parity, age at menarche
and contraceptive pill use. Risk estimates were not mark-
edly different when women with a first primary diagnosis of
ovarian cancer were excluded, with a RR (95% CI) for the
≥ 28 CAG cut-point of 0.85 (0.49–1.47) for BRCA1 muta-
tion carriers (P = 0.6), and 1.12 (0.0.55–2.27) for BRCA2
mutation carriers (P = 0.8).
Results using the weighted Cox regression approach indi-
cated that RR estimates were not materially affected by
possible ascertainment biases. For example, for the ≥ 28
CAG cut-point, the RR (95% CI) adjusted for group and
ethnicity was 0.74 (0.33–1.66) for BRCA1 carriers (P =
0.5) and 0.94 (0.32–2.77) for BRCA2 carriers (P = 0.9).
For average CAG length, the RR (95% CI) adjusted for
group and ethnicity was 1.01 (0.94–1.10) for BRCA1 car-
riers (P = 0.8) and 0.96 (0.82–1.11) for BRCA2 carriers (P
= 0.6). These results are consistent with the findings of
Antoniou and coworkers (unpublished data), in which both
weighted and unweighted Cox regression analyses give
similar estimates when the true RR is 1.0.
There was also no compelling evidence for an effect of
mutation position on risk associated with AR CAG repeat
length. BRCA1 mutations were firstly divided by position
relative to amino acid 1365 (nucleotide 4213), because
mutations 5' of this have been reported to exhibit markedly
decreased AR transactivation ability [11]. The RR (95% CI)
for the ≥ 28 CAG cut-point analyses were 0.93 (0.53–
1.64) for domain 1 (P = 0.8) and 0.35 (0.12–1.02) for
domain 2 (P = 0.06), with marginal evidence for an interac-
tion (P = 0.1). BRCA1 mutations were also divided by posi-
tion relative to amino acid 1065 (nucleotide 3311),
because the 3' end of the BRCA1  fragment has been
shown in vitro to bind the AR amino-terminal domain con-
taining the CAG-encoded polyglutamine tract [11]. The RR
(95% CI) for the ≥ 28 CAG cut-point analyses were 0.98
(0.54–1.78) for domain 1 (P = 0.9) and 0.45 (0.16–1.23)Breast Cancer Research    Vol 7 No 2    Spurdle et al.
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for domain 2 (P = 0.1), with no evidence for an interaction
(P = 0.3)
There was no convincing rationale for stratification of the
BRCA2 mutation carriers by mutation position, in that there
is no published information available with regard to the
domains of BRCA2 required for BRCA2–AR interaction or
to the effect of BRCA2 mutation position on the BRCA2–
AR interaction. However, because a single report has
shown that the BRCA2  L1042X mutation does not
enhance AR transactivation [10], mutations 5' to this muta-
tion site might be expected to have similar drastic conse-
quences, and to convey increased risk among carriers with
large AR CAG alleles. Stratification by mutation position
relative to amino acid 1042 (nucleotide 4213) divided the
BRCA2 carrier sample into two subgroups of 42 and 177
individuals. None of the 42 individuals with mutations in
domain 1 had alleles with repeat length ≥ 28 CAG,
precluding estimates of risk for this subgroup. However,
there was no evidence for increased risk among BRCA2
carriers with mutations in the domain 5' to amino acid
L1024, with a RR (95% CI) for the ≥ 28 CAG cut-point of
1.11 (0.54–2.30) for the 5' domain (P = 0.8).
Discussion
Our study found no evidence to support the previously
reported association of AR  allele length with increased
breast cancer risk in BRCA1 carriers [7]. The hypothesis-
generating study estimated a 1.8-fold risk (95% CI 1.1–
3.1) in BRCA1 carriers with at least one AR allele length ≥
28 CAG repeats, and increasing risks of 2.7-fold and 4.5-
fold for the ≥ 29 CAG repeat and ≥ 30 CAG repeat cut-
points, respectively [7]. The RR estimated by our study for
≥ 28 repeats was 0.74, and the upper 95% confidence
limit (1.28) excludes the effect size reported by Rebbeck
and coworkers [7]. Moreover, there was no evidence for
increased RRs at the ≥ 29 or ≥ 30 cut-points. Given that we
had approximately 80% or more power to detect risk esti-
mates previously reported for the ≥ 29 cut-point [7], these
results suggest that if there is any increased risk for large
number of CAG repeats among BRCA1 mutation carriers,
then it is of much lower magnitude than was first reported.
Table 2
Risk associated with AR CAG repeat length amongst BRCA1 mutation carriers
Risk allele Adjusted group, ethnicity Adjusted group, ethnicity and additional variables
P RR (95% CI) P RR (95% CI)
AR ≥ 28 CAG 0.3 0.74 (0.42–1.29) 0.6 0.88 (0.53–1.46)
AR ≥ 29 CAG 0.3 0.76 (0.43–1.33) 0.7 0.89 (0.54–1.48)
AR average CAG 0.5 1.02 (0.96–1.09) 0.3 1.03 (0.97–1.10)
AR small CAG 0.3 1.03 (0.97–1.09) 0.2 1.04 (0.98–1.10)
AR large CAG 0.9 1.01 (0.96–1.06) 0.6 1.01 (0.97–1.06)
First primary breast cancer diagnosis was considered an event (status affected), whereas first primary ovarian cancers were censored as 
unaffected at age of diagnosis, and individuals without breast or ovarian cancer were censored as unaffected at age at interview. All individuals 
were censored as unaffected at age of prophylactic mastectomy prior to diagnosis/interview. Analyses were adjusted for source group, ethnicity, 
year of birth and hormonal variables oophorectomy, parity, age at menarche and contraceptive pill use. Oophorectomy and parity were treated as 
time-dependent variables from age at first variable event. Analyses were conducted using unweighted Cox regression.
Table 3
Risk associated with AR CAG repeat length amongst BRCA2 mutation carriers
Risk allele Adjusted group, ethnicity Adjusted group, ethnicity and additional variables
P RR (95% CI) P RR (95% CI)
AR ≥ 28 CAG 0.8 1.12 (0.55–2.25) 0.9 1.04 (0.47–2.32)
AR ≥ 29 CAG 0.8 0.88 (0.37–2.09) 0.8 0.90 (0.32–2.52)
AR average CAG 0.7 0.98 (0.91–1.06) 1.0 1.00 (0.92–1.09)
AR small CAG 0.6 0.98 (0.90–1.06) 1.0 1.00 (0.92–1.09)
AR large CAG 0.9 0.99 (0.93–1.06) 1.0 1.00 (0.93–1.07)
First primary breast cancer diagnosis was considered an event (status affected), whereas first primary ovarian cancers were censored as 
unaffected at age of diagnosis, and individuals without breast or ovarian cancer were censored as unaffected at age at interview. All individuals 
were censored as unaffected at age of prophylactic mastectomy before diagnosis/interview. Analyses were adjusted for source group, ethnicity, 
year of birth, and hormonal variables oophorectomy, parity, age at menarche, and contraceptive pill use. Oophorectomy and parity were treated as 
time-dependent variables from age at first variable event. Analyses were conducted using unweighted Cox regression.Available online http://breast-cancer-research.com/content/7/2/R176
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Rebbeck and coworkers [7] found no effect of AR CAG
repeat length when considered as a continuous variable,
and our study likewise found no evidence for an association
with shorter, larger, or average CAG repeat length.
Other published studies have found no evidence to support
an association between AR CAG repeat length and breast
cancer risk in BRCA2 mutation carriers [8,9]. Our study
also found no evidence in support of an association.
Although our sample of 220 BRCA2 carriers was not suffi-
ciently large to provide precise estimates of risk, the upper
95% confidence limits imply that a 2.5-fold risk associated
with ≥ 28 or ≥ 29 repeat lengths is unlikely.
Conclusion
Our analyses provide no support for an association
between AR CAG repeat length and breast cancer risk in
either BRCA1 or BRCA2 mutation carriers. An increased
risk associated with ≥ 28 or ≥ 29 repeat lengths is not com-
patible with our data. Weak associations cannot be
excluded, but analyses involving much larger numbers of
carriers would be required to evaluate this possibility.
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